To determine the contribution of conjunctival mast cells to the allergen-specific inflammatory responses in eyes with allergic conjunctivitis and to test the hypothesis that mast cells act as mediators of the early phase response. Methods: The participation of mast cells in allergen-induced inflammatory cell recruitment was studied in an experimental murine model of allergic conjunctivitis. Experimental allergic conjunctivitis was induced by a single or multiple sensitizing injections of an allergen. Allergic diseases affect approximately one-third of the population and constitute one of the major health care problems in the Western world [1] . Ocular allergy is an example of an IgE-mediated immediate hypersensitivity reaction. These reactions are initiated by the cross-linking of IgE by an allergen, and their effects are mediated by the degranulation of mast cells. Immediate hypersensitivity reactions are characterized by early phase and late phase responses. The early phase response develops immediately after the exposure to the allergen, and clinical symptoms and signs such as itching, chemosis, and congestion are manifested very quickly. This is followed by the late phase response after 8-24 h, which is characterized by conjunctival eosinophilia and neutrophilia.
Allergic diseases affect approximately one-third of the population and constitute one of the major health care problems in the Western world [1] . Ocular allergy is an example of an IgE-mediated immediate hypersensitivity reaction. These reactions are initiated by the cross-linking of IgE by an allergen, and their effects are mediated by the degranulation of mast cells. Immediate hypersensitivity reactions are characterized by early phase and late phase responses. The early phase response develops immediately after the exposure to the allergen, and clinical symptoms and signs such as itching, chemosis, and congestion are manifested very quickly. This is followed by the late phase response after 8-24 h, which is characterized by conjunctival eosinophilia and neutrophilia.
Eosinophilic inflammation is not only a hallmark of allergic conjunctivitis but also a major cause for tissue injury and remodeling. Therefore, to understand how this response develops or is exacerbated is important in developing an effective strategy to combat ocular allergy.
The role played by T cells in the eosinophilic inflammation of severe allergic conjunctivitis has been Correspondence to: Dr. Dai Miyazaki, MD, Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, 36-1 Nishicho, Yonago, Tottori, Japan, 683-8504; Phone: 81-859-38-6617; FAX: 81-859-38-6619; email: dm@grape.med.tottori-u.ac.jp gaining interest. For example, we have reported that the potent inhibitor of T cell activation, tacrolimus, will reduce the symptoms and signs of a severe form of allergic conjunctivitis involving a corneal ulcer [2] . In experimental settings, an eosinophil infiltration can occur independent of the presence of mast cells [3, 4] . Thus, the question arises as to how mast cells contribute to ocular inflammatory cell recruitment. Are conjunctival mast cells simply serving to induce the clinical symptoms during the early phase and play a subordinate part in the final late phase inflammatory process?
To answer this question and to evaluate the contribution of mast cells to the late phase inflammatory process, we have developed a mast cell reconstituted model. Bone marrowderived mast cells (BMMCs) are commonly used to restore mast cell populations. However, these cells are not appropriate for the analyses of ocular responses because BMMCs have a distinct lineage from mast cells in connective tissues such as those residing in the conjunctiva [5] . Indeed, important maturation markers of connective tissue type mast cells such as CCR3, a receptor of eotaxin-1, are not expressed by BMMCs [5] . For inflammatory responses, mast cells are recruited to the effector site from the bone marrow, and they mature in situ presumably by differentiating into an inflammatory phenotype by chemokine receptors. Thus, conjunctival allergic responses are mixed phenomena induced by tissue-residing mast cells and newly recruited mast cells.
We have developed an adoptive transfer model in which the conjunctiva of mast cell-deficient mice is reconstituted with conjunctival mast cells from wild type mice. After the induction of allergen-specific allergic conjunctivitis, we carefully assessed the contribution of mast cells to the early phase and late phase responses. w-v mice carry point mutations in the transmembrane and kinase domains and therefore lack the ability to activate the signaling cascade initiated by its ligand, stem cell factor (SCF). The mast cell deficiency is greater than 99% in the systemic circulation, airway, intestine, and skin of these mice [6] . and wild type mice were allergensensitized using protocols developed in our laboratory [7] [8] [9] . We used two established immunization protocols; one used a single exposure and the other using multiple exposures [7] [8] [9] . In both models, the inflammatory cell recruitment in the late phase is dependent on mast cell degranulation.
METHODS

Animals
For the single exposure protocol [8] , anesthetized mice were injected with a suspension of 50 μg of ragweed pollen (ICN, Aurora, OH) and 1 mg of aluminum hydroxide (Sigma, St. Louis, MO) into the left hind footpad. On day 22, conjunctivitis was induced by topical application of 1.5 mg of ragweed suspended in 10 μl of phosphate buffered saline (PBS). Control mice were mock-sensitized with aluminum hydroxide and challenged identically with the ragweed suspension.
The clinical responses were graded using a modified version of our published method 20 min after the allergen challenge [7] [8] [9] . Conjunctival edema, lid edema, tear/ discharge, and conjunctival redness were graded from 0 to 4 by an observer who was masked to the treatment protocol of the mice (Table 1 ). The cumulative clinical score was calculated as the sum of the scores of each of the four parameters with a range from 0 to 16.
For the repeated exposure protocol, groups of mice (10 mice per group) were initially injected intraperitoneally with 1 mg of aluminum hydroxide that was conjugated with cat dander extract (200 BAU/mouse; ALK Laboratories, Horsholm, Denmark) on days 1, 14, and 24. Control mice were injected with the vehicle of the dander extract on the same days. Concomitantly, aluminum hydroxide (25 μg/eye)-conjugated cat dander extract (10,000 BAU/ml) or vehicle was applied topically to the eye on days 1, 2, 3, 7, and 14. Thereafter, mice were exposed to the allergen for sensitization once a week by topical instillation of cat dander extract (10,000 BAU/ml) or vehicle onto the eye. Eight weeks after the initial sensitization, affinity-purified Fel d 1 (0.5 mg/ml), cat dander extract (10,000 BAU/ml; Greer Laboratories, Lenoir, NC), or vehicle was applied to the eyes (10 μl /eye) for two consecutive days for the final priming. The early phase and late phase responses were elicited by instilling cat hair allergen (Fel d 1) to all mice 24 h after the last allergen sensitization.
For histological evaluation, mice were sacrificed 2 h after the challenge to investigate the early phase response and 24 h after the challenge to examine the late phase inflammatory response. The tissues from the eyes were fixed in 4% paraformaldehyde and embedded in HistoResin (Leica The clinical responses were graded at 20 min after allergen challenge.
Instruments GmbH, Heidelberg, Germany). Serial sagittal sections (3 μm thick) were cut and stained with toluidine blue, Giemsa, or hematoxylin and eosin. Three serial sections of the conjunctival tissue were examined from each eye to determine the number of inflammatory cells recruited into the conjunctiva. A masked observer counted the number of cells under a 400X microscopic field.
Measurement of allergen-specific IgE and IgG1 antibodies:
Sera were collected by cardiac puncture 24 h after the allergen challenge. The Fel d 1-specific IgE and IgG1 levels were measured by ELISA [9, 10] . The sera were pipetted onto a Fel d 1-coated microtiter plate (Maxisorp; Nalge Nunc International KK, Tokyo, Japan), incubated with biotinconjugated anti-IgE (BD Biosciences, Franklin Lakes, NJ) or anti-IgG1 (SouthernBiotech, Birmingham, AL) antibodies, and developed for peroxidase-based substrate detection.
Isolation and FACS analysis of mast cells from the conjunctiva:
The protocol to isolate crude conjunctival mast cells was developed and optimized based on an enzymatic digestion method. Briefly, the conjunctiva of eight-week-old to 12-week-old SWR/J mice were cut into fragments and incubated in RPMI1640 medium supplemented with 10% fetal bovine serum, 1.5 mg/ml collagenase (Nitta Gelatin, Osaka, Japan), 0.5 mg/ml hyaluronidase (Sigma), and 0.5 mg/ ml DNase I (Sigma) for 2 h at 37 °C. The dispersed cells were filtered through a 40 μm cell strainer, layered on an isotonic Percoll density medium (density=1.041, Amersham Pharmacia Biotech, Piscataway, NJ), and centrifuged at 800x g for 20 min [11] . The pellet was cultured in RPMI1640 with murine recombinant IL-3 (10 ng/ml; Peprotech, Rocky Hill, NJ), recombinant SCF (10 ng/ml; Peprotech), and 5% serum for two days. Colony-forming, non-adherent mast cells were harvested by gentle shaking and decanting of the flasks. The cells were then layered onto a Percoll density medium (density=1.041) and centrifuged at 800x g for 20 min.
To precisely evaluate the roles of mast cells, a further purification protocol was developed for the functional analyses. Based on preliminary FACS analyses, contaminated populations included dendritic cells, macrophages, and plasma cells, which were characterized by the expression of CD4, CD8a, CD11b, B220, and PDCA-1. These markers were selected and confirmed for appropriateness for depletion markers based on the co-expression of mature mast cell markers such as CCR3 and CXCR3 (data not shown). To deplete these cells, we used a magnet-based negative depletion method to obtain maximum recovery. Briefly, cells were blocked by anti-CD32 (Clone 93; eBiosciences, San Diego, CA) and labeled with rat anti-CD4, rat anti-CD8a, rat anti-CD11b, rat anti-B220 (all from eBiosciences), and rat anti-PDCA-1 (Miltenyi Biotec Inc., Auburn, CA). The labeled fractions were depleted using anti-rat immunoglobulin κ chain antibody-conjugated microbeads (IMag; BD Biosciences).
For FACS analyses, cultured mast cells were blocked by anti-CD32 and stained for immunofluorescence analysis. The 
RESULTS
Mast cells required for early phase response of allergic conjunctivitis:
We first examined whether the tissues on the ocular surface of Kit w /Kit w-v mice had any mature mast cells that could be identified by the presence of metachromatic granules. An earlier investigation showed that mast cells were not present in different mucosal tissues of these mice [6] , and in confirmation, we found that mast cells were absent in the conjunctiva, eyelids, and choroid of naïve Kit
To evaluate the contribution of mast cells to the ocular symptoms during the early phase allergic response, we challenged sensitized mice with the allergen following the single exposure protocol. Mice were assessed for clinical signs including conjunctival edema, conjunctival redness, tearing, and lid edema. The degree of inflammation during the early phase is summarized as clinical scores in Figure 1A mice appeared not specific for the allergen because no significant difference was observed between the sensitized and mock-sensitized mice. This is consistent with the concept that conjunctival mast cells mediate the clinical signs after the allergen challenge.
To examine the contribution of mast cells to the clinical signs in allergic inflammation in more detail, we restored mice. Conjunctival mast cells, isolated by lineage marker depletion after density-gradient separation, were tested for allergen-induced degranulation and mast cell-restricted proteases. The conjunctiva-derived mast cells expressed high levels of the connective tissue type mast cell proteases, mMCP-5, mMCP-6, and mMCP-7. When these cells were sensitized with anti-DNP-specific IgE and exposed to DNPalbumin, they appropriately degranulated in an allergenspecific manner (data not shown).
Peripheral tissues, including the conjunctiva, are continuously replenished by the migration of bone marrowderived mast cells. To exclude any effect of newly immigrated cells from the bone marrow, the conjunctiva of mast celldeficient mice were reconstituted with the conjunctivaderived mast cells from the wild type mice.
The conjunctival mast cells that were expressing CXCR3 as a maturation marker of conjunctival mast cells ( Figure 1D ) [5] and isolated from naive wild type mice were adoptively transferred into the allergen-sensitized Kit Figure 1C ). In contrast, mice injected with the conjunctival mast cells had levels of mMCP-5 and mMCP-6 that were comparable to those of wild type mice ( Figure 1C ). This confirmed that the transferred mast cells maintained the properties of the connective tissue type as conjunctival mast cells.
To examine their homing ability, real time PCR was conducted to examine levels of mast cell-specific proteases in the draining lymph nodes of the adoptive transfer mice. Neither mMCP-5 nor mMCP-6 was detected in the adoptive transfer mice (below detection limits). This indicated that the transferred mast cells remained in the conjunctiva and did not migrate elsewhere.
When mice, was observed in both sensitized and mock-sensitized adoptive transfer mice. The sensitized mice had significantly more allergen-specific mast cell degranulation than the mocksensitized mice (53% versus 17%, p<0.05; Figure 1B ). The restored response was indistinguishable from that of the wild type mouse response, supporting the validity of our adoptive transfer model using Kit We have shown that the degree of mast cell degranulation is linearly correlated with the clinical scores [9] . Thus, conjunctival mast cells are necessary and sufficient for activation of the acute phase clinical responses.
In clinical settings, allergic symptoms are provoked after repeated exposure to an allergen. We have shown that repeated exposure to an allergen aggravated the clinical signs and altered mast cell restricted proteases [12] Figure 2 ). The clinical signs were completely suppressed, and the tear/discharge score was depressed by 78%.
To determine whether mast cell deficiency affected antigen-specific B cell and T cell responses during allergic conjunctivitis, levels of allergen-specific IgE and IgG1 were measured after the final allergen challenge. The titers of IgE and IgG reflect the function of both B cells and T cells because an increased production of IgE and IgG1 requires numerous B cell and T cell processes including antigen presentation, antigen-specific T cell expansion, class switch recombination of B cells, and specific antibody production.
Allergen-specific IgE and IgG1 were appropriately induced following the allergen challenge in sensitized wild type mice but not in mock-sensitized wild type mice ( Figure  3 mice, the allergen-specific eosinophil recruitment in the transferred mice was completely restored ( Figure 4B ). These observations clearly demonstrated that the late phase eosinophil infiltration is dependent on mast cell activity. Interestingly, we did not observe an increase in neutrophil recruitment in any of the sensitized animals compared to their mock-sensitized counterparts ( Figure 4B ).
We next sensitized mice using the repeated allergen exposure model [9] and then evaluated mast cell contributions to the local activation or preconditioning of bystander cells or mast cells. In wild type mice, an allergen challenge significantly increased the number of conjunctival eosinophils in the sensitized animals but not in the mock-sensitized animals ( Figure 5 ). However, the number of conjunctival eosinophils was not significantly increased in sensitized Kit 
DISCUSSION
Our results demonstrated important aspects of mast cell involvement in ocular allergy (i.e., the activation of locally residing conjunctival mast cells) after an allergen exposure induced the recruitment of eosinophils. This is in marked contrast to the conclusions of Ueta et al. [4] who reported that mast cells were not required for eosinophil recruitment in allergic conjunctivitis using antigen-sensitized, mast celldeficient mice. However, their conclusion considered only one aspect of allergic conjunctivitis. It is known that allergic conjunctivitis is triggered by the mast cell degranulationmediated cascade, and this needs to be clearly shown in the model being evaluated for mast cell dependence. However, eosinophilia is a good indicator of allergic conjunctivitis. Indeed, the mast cell-mediated activation, which was not presented in their report, primes Th2-type T cells-dependent eosiophil recruitment. For example, the transfer of Th2-type T cells can induce massive eosinophilic inflammation. Also, in the corneal transplantation model, inflammatory responses can be eosinophilic in certain donor and recipient combinations [13] . Thus, one can create experimental settings where the involvement of mast cells is least required. Evaluation of eosinophilic inflammation in allergic conjunctivitis needs to be evaluated by the activation of mast cells.
We do not argue that eosinophilia can occur with a minimal activation of mast cells. This situation can be created by repetitive and strong immunizations. Ueta et al. [4] used an intradermal injection of ragweed allergen followed by multiple boosting by two intraperitoneal injections and four repetitive allergen exposures. This would usually result in a vigorous T cell-mediated response and clonal expansion that should culminate in a massive eosinophil recruitment after an antigen challenge [3, 14, 15] . In addition, they claimed that the attenuated protocol (one intradermal injection followed by one intraperitoneal injection) still provoked allergen-induced eosinophil recruitment in mast cell-deficient mice. However, this model also appeared to be independent of IgE-mediated mast cell degranulation because no allergen-specific IgE was detected in the sera of their experimental mice. The contribution of mast cells to the eosinophilic responses can be explained by the properties of the cytokines and chemokines released upon activation. For example, conjunctival mast cells activated by FcεRI produce IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12, GM-CSF, MIP-1α, and TNF-α (unpublished observations). IL-3 and IL-5 are particularly likely to contribute to eosinophilic inflammation as they play critical roles in eosinophil development, survival, and recruitment [16] . Other mast cell-derived mediators that might contribute to eosinophil activity in ocular hypersensitivity include the leukotrienes, B4 and D4, and tryptases [17, 18] . These observations are consistent with the idea that T cell priming is required for mast cell-related eosinophilia and support our findings that mast cells mediated the eosinophil recruitment in the late phase inflammation.
It has been suggested that the role of conjunctival mast cells was to induce neutrophilic inflammation. For example, when mast cell degranulation is induced in the conjunctiva by compound 48/80, the resulting conjunctivitis is characterized by infiltration of neutrophils, macrophages, and CD4 + T lymphocytes but surprisingly few eosinophils [19] . This is in marked contrast to our observations, which showed that neutrophilic inflammation does not require conjunctival mast cells. This might be due to the relative low levels of neutrophilic cytokines derived from mature mast cells. The mononuclear cells and macrophages are the major sources of neutrophilic cytokines such as TNF-α and MIP-1α. We suggest that the neutrophilic inflammation induced by compound 48/80 may be explained by such mediators derived from mononuclear cells and macrophages, which are indirectly stimulated by mast cell-derived chemokines or cytokines.
In conclusion, our new mast cell reconstituted model is a better method to investigate what role conjunctiva-residing mast cells play in experimental allergic conjunctivitis. This allowed us to evaluate the direct contribution of mast cells to eosinophilic inflammation. Our data support the idea that regulation of mast cell activation and maturation in addition to current therapy to suppress mast cell degranulation might be promising therapeutic strategies. Direct targeting of c-Kit, mast cell-derived chemokines, or chemokine receptors might also yield good therapeutic results [9, [20] [21] [22] .
